[1] Chan DC.Mitochondria:dynamic organelles in disease, aging, and development[J].Cell, 2006, 125(7):1241-1252.DOI:10.1016/j.cell.2006.06.010.
[2] Heller A, Brockhoff G, Goepferich A.Targeting drugs to mitochondria[J].Eur J Pharm Biopharm, 2012, 82(1):1-18.DOI:10.1016/j.ejpb.2012.05.014.
[3] D′Souza GG, Wagle MA, Saxena V, et al.Approaches for targeting mitochondria in cancer therapy[J].Biochim Biophys Acta, 2011, 1807(6):689-696.DOI:10.1016/j.bbabio.2010.08.008.
[4] Rwigema JC, Beck B, Wang W, et al.Two strategies for the development of mitochondrion-targeted small molecule radiation damage mitigators[J].Int J Radiat Oncol Biol Phys, 2011, 80(3):860-868.DOI:10.1016/j.ijrobp.2011.01.059.
[5] Jiang J, Stoyanovsky DA, Belikova NA, et al.A mitochondria-targeted triphenylphosphonium-conjugated nitroxide functions as a radioprotector/mitigator[J].Radiat Res, 2009, 172(6):706-717.DOI:10.1667/RR1729.1.
[6] Zhou J, Zhao WY, Ma X, et al.The anticancer efficacy of paclitaxel liposomes modified with mitochondrial targeting conjugate in resistant lung cancer[J].Biomaterials, 2013, 34(14):3626-3638.DOI:10.1016/j.biomaterials.2013.01.078.
[7] Reily C, Mitchell T, Chacko BK, et al.Mitochondrially targeted compounds and their impact on cellular bioenergetics[J].Redox Biol, 2013, 1(1):86-93.DOI:10.1016/j.redox.2012.11.009.
[8] Mao P, Manczak M, Shirendeb UP, et al.MitoQ, a mitochondria-targeted antioxidant, delays disease progression and alleviates pathogenesis in an experimental autoimmune encephalomyelitis mouse model of multiple sclerosis[J].Biochim Biophys Acta, 2013, 1832(12):2322-2331.DOI:10.1016/j.bbadis.2013.09.005.
[9] Milagros RM, Victor VM.Targeting antioxidants to mitochondria and cardiovascular diseases:the effects of mitoquinone[J].Med Sci Monit, 2007, 13(7):RA132-145.
[10] Li L, Brichard L, Larsen L, et al.Radiosynthesis of 11-(18F) fluoroundecyltriphenylphosphonium(MitoF) as a potential mitochondria-specific positron emission tomography radiotracer[J].J Labelled Comp Radiopharm, 2013, 56(14):717-721.DOI:10.1002/jlcr.3109.
[11] Zhao K, Zhao GM, Wu D, et al.Cell-permeable peptide antioxidants targeted to inner mitochondrial membrane inhibit mitochondrial swelling, oxidative cell death, and reperfusion injury[J].J Biol Chem, 2004, 279(33): 34682-34690.DOI:10.1074/jbc.M402999200.
[12] Birk AV, Chao WM, Bracken C, et al.Targeting mitochondrial cardiolipin and the cytochrome c/cardiolipin complex to promote electron transport and optimize mitochondrial ATP synthesis[J].Br J Pharmacol, 2014, 171(8):2017-2028.DOI:10.1111/bph.12468.
[13] Wipf P, Xiao J, Jiang J, et al.Mitochondrial targeting of selective electron scavengers:synthesis and biological analysis of hemigramicidin-TEMPO conjugates[J].J Am Chem Soc, 2005, 127(36):12460-12461.DOI:10.1021/ja053679l.
[14] Hoye AT, Davoren JE, Wipf P, et al.Targeting mitochondria[J].Acc Chem Res, 2008, 41(1):87-97.DOI:10.1021/ar700135m.
[15] Xun Z, Rivera-Sánchez S, Ayala-Peña S, et al.Targeting of XJB-5-131 to mitochondria suppresses oxidative DNA damage and motor decline in a mouse model of Huntington′s disease[J].Cell Rep, 2012, 2(5):1137-1142.DOI:10.1016/j.celrep.2012.10.001.
[16] Gruber J, Fong S, Chen CB, et al.Mitochondria-targeted antioxidants and metabolic modulators as pharmacological interventions to slow ageing[J].Biotechnol Adv, 2013, 31(5):563-592.DOI:10.1016/j.biotechadv.2012.09.005.
[17] Yamada Y, Akita H, Kogure K, et al.Mitochondrial drug delivery and mitochondrial disease therapy—an approach to liposome-based delivery targeted to mitochondria[J].Mitochondrion, 2007, 7(1/2):63-71.DOI:10.1016/j.mito.2006.12.003.
[18] Dolezal P, Likic V, Tachezy J, et al.Evolution of the molecular machines for protein import into mitochondria[J].Science, 2006, 313(5785):314-318.DOI:10.1126/science.1127895.
[19] Bohnert M, Pfanner N, van der Laan M.A dynamic machinery for import of mitochondrial precursor proteins[J].FEBS Lett, 2007, 581(15):2802-2810.DOI:10.1016/j.febslet.2007.03.004.
[20] Murcha MW, Kmiec B, Kubiszewski-Jakubiak S, et al.Protein import into plant mitochondria:signals, machinery, processing, and regulation[J].J Exp Bot, 2014, 65(22):6301-6335.DOI:10.1093/jxb/eru399.
[21] Bacman SR, Williams SL, Duan D, et al.Manipulation of mtDNA heteroplasmy in all striated muscles of newborn mice by AAV9-mediated delivery of a mitochondria-targeted restriction endonuclease[J].Gene Ther, 2012, 19(11):1101-1106.DOI:10.1038/gt.2011.196.
[22] Bacman SR, Williams SL, Hernandez D, et al.Modulating mtDNA heteroplasmy by mitochondria-targeted restriction endonucleases in a 'differential multiple cleavage-site' model[J].Gene Ther, 2007, 14(18):1309-1318.DOI:10.1038/sj.gt.3302981.
[23] Srivastava S, Moraes CT.Manipulating mitochondrial DNA heteroplasmy by a mitochondrially targeted restriction endonuclease[J].Hum Mol Genet, 2001, 10(26):3093-3099.DOI:10.1093/hmg/10.26.3093.
[24] Tanaka M, Borgeld HJ, Zhang J, et al.Gene therapy for mitochondrial disease by delivering restriction endonuclease SmaI into mitochondria[J].J Biomed Sci, 2002, 9(6 Pt 1):534-541.DOI:10.1007/BF02254980.
[25] Esaki M, Kanamori T, Si N, et al.Two distinct mechanisms drive protein translocation across the mitochondrial outer membrane in the late step of the cytochrome b(2)import pathway[J].Proc Natl Acad Sci USA, 1999, 96(21):11770-11775.  doi: 10.1073/pnas.96.21.11770
[26] Kulawiak B, Höpker J, Gebert M, et al.The mitochondrial protein import machinery has multiple connections to the respiratory chain[J].Biochim Biophys Acta, 2013, 1827(5):612-626.DOI:10.1016/j.bbabio.2012.12.004.
[27] Torchilin VP, Rammohan R, Weissig V, et al.TAT peptide on the surface of liposomes affords their efficient intracellular delivery even at low temperature and in the presence of metabolic inhibitors[J].Proc Natl Acad Sci USA, 2001, 98(15): 8786-8791.DOI:10.1073/pnas.151247498.
[28] Joliot A, Prochiantz A.Transduction peptides:from technology to physiology[J].Nat Cell Biol, 2004, 6(3):189-196.DOI:10.1038/ncb0304-189.
[29] Torchilin VP, Rammohan R, Weissig V, et al.TAT peptide on the surface of liposomes affords their efficient intracellular delivery even at low temperature and in the presence of metabolic inhibitors[J].Proc Natl Acad Sci USA, 2001, 98(15):8786-8791.DOI:10.1073/pnas.151247498.
[30] Del GV, Mackenzie JA, Payne RM.Targeting proteins to mitochondria using TAT[J].Mol Genet Metab, 2003, 80(1/2):170-180.DOI:10.1016/j.ymgme.2003.08.017.
[31] Shokolenko IN, Alexeyev MF, LeDoux SP, et al.TAT-mediated protein transduction and targeted delivery of fusion proteins into mitochondria of breast cancer cells[J].DNA Repair(Amst), 2005, 4(4):511-518.DOI:10.1016/j.dnarep.2004.11.009.
[32] Marin SE, Mesterman R, Robinson B, et al.Leigh syndrome associated with mitochondrial complex I deficiency due to novel mutations In NDUFV1 and NDUFS2[J].Gene, 2013, 516(1):162-167.DOI:10.1016/j.gene.2012.12.024.
[33] Mileshina D, Ibrahim N, Boesch P, et al.Mitochondrial transfection for studying organellar DNA repair, genome maintenance and aging[J].Mech Ageing Dev, 2011, 132(8/9):412-423.DOI:10.1016/j.mad.2011.05.002.
[34] D′Souza GG, Rammohan R, Cheng SM, et al.DQAsome-mediated delivery of plasmid DNA toward mitochondria in living cells[J].J Control Release, 2003, 92(1/2):189-197.DOI:10.1016/S0168-3659(03)00297-9.
[35] Kogure K, Moriguchi R, Sasaki K, et al.Development of a non-viral multifunctional envelope-type nano device by a novel lipid film hydration method[J].J Control Release, 2004, 98(2):317-323.DOI:10.1016/j.jconrel.2004.04.024.
[36] Kajimoto K, Sato Y, Nakamura T, et al.Multifunctional envelope-type nano device for controlled intracellular trafficking and selective targeting in vivo[J].J Control Release, 2014, 190:593-606.DOI:10.1016/j.jconrel.2014.03.058.
[37] Wang XX, Li YB, Yao HJ, et al.The use of mitochondrial targeting resveratrol liposomes modified with a dequalinium polyethylene glycol-distearoylphosphatidyl ethanolamine conjugate to induce apoptosis in resistant lung cancer cells[J].Biomaterials, 2011, 32(24):5673-5687.DOI:10.1016/j.biomaterials.2011.04.029.
[38] Biswas S, Dodwadkar NS, Deshpande PP, et al.Liposomes loaded with paclitaxel and modified with novel triphenylphosphonium-PEG-PE conjugate possess low toxicity, target mitochondria and demonstrate enhanced antitumor effects in vitro and in vivo[J].J Control Release, 2012, 159(3):393-402.DOI:10.1016/j.jconrel.2012.01.009.
[39] Yamada Y, Harashima H.Mitochondrial drug delivery systems for macromolecule and their therapeutic application to mitochondrial diseases[J].Adv Drug Deliv Rev, 2008, 60(13/14):1439-1462.DOI:10.1016/j.addr.2008.04.016.